Compare Bristol-Myers Squibb Co (BMY) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs SkyWest Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while SkyWest Inc trades at $97.36 (market cap $3.85B). The key difference: Bristol-Myers Squibb Co is far larger — about 30.2× SkyWest Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| BMY | SKYW | |
|---|---|---|
Market Cap | $116.30B | $3.85B |
Sector | Health | Technology |
52-Week High | $62.37 | $123.72 |
52-Week Low | $42.60 | $78.40 |
Enterprise Value | $152.24B | $5.70B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SkyWest (SKYW) trades at $97.78, down 1.95% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows strong fundamentals with a P/E of 9.32 and net income margin of 10.42%, supported by recent earnings beats. Analyst consensus is bullish with a $109.33 price target. Recent news includes a key executive appointment and attention to fuel cost pressures in the airline industry.
The outlook for SKYW is positive given its attractive valuation and profitability, but risks include rising fuel expenses and industry volatility. With no sell ratings and 56% buy consensus, the stock presents a compelling opportunity for upside, though investors should monitor cost management and quarterly results closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
